If you have been reading about peptide agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-05. Numbers and descriptions here follow the published literature rather than marketing material.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
==== Minor sources ==== Volcanic eruptions may emit PAHs. Certain PAHs such as perylene can also be generated in anaerobic sediments from existing organic material, although it remains undetermined whether abiotic or microbial processes drive their production.
==== March ==== On 1 March, clashes broke out between Syrian caretaker government forces and local Druze armed groups responsible for community protection in Jaramana, during the security operation launched by Syrian authorities on the suburb. Members of the Jaramana Shield Brigade were involved in the clashes. During a violent altercation which erupted in Al-Seuof Square between two General Security Service members and local armed residents, one local gunman sustained serious injuries, requiring hospitalization, while authorities took the two security personnel into custody. In the clash at Al-Seuof Square, the wounded local gunman was taken to Al-Mujtahed Hospital for medical treatment. But Hay'at Tahrir al-Sham militants arrived at the hospital where the situation escalated when one of the wounded man's escorts allegedly made blasphemous remarks about Allah. This prompted members of Hayat Tahrir al-Sham present at the hospital to physically assault and subsequently detain the companions, resulting in one confirmed fatality among security forces. The clashes ended on 2 March 2025, after the entry of General Security Service into Jaramana. A meeting was held in March 2025 between Druze spiritual leader Hikmat al-Hijri, Yahya Al-Hajjar, the head of the Men of Dignity, Suleiman Abdul Baqi, the leader of Ahrar Jabal al-Arab, and Shakib Azam, the leader of Al-Jabal Brigade, in which it was agreed that the General Security Service would be "re-activated" in the governorate, as long as the people involved were from Suwayda.
=== Partnerships === In 2012, Safeway invested $350 million into retrofitting 800 locations with clinics that would offer in-store blood tests. After many missed deadlines and questionable results from a trial clinic at Safeway's corporate offices, the deal was terminated in 2015. In 2013, Theranos partnered with Walgreens to offer in-store blood tests at more than 40 locations. Although Theranos blood tests were reportedly used on drug trial patients for GlaxoSmithKline and Pfizer, both companies stated in October 2015 that there were no active projects with Theranos. In June 2016, Walgreens terminated its partnership with Theranos. In November 2016, it filed a suit against Theranos in federal court in Delaware for breach of contract. In June 2017, Theranos reported to investors that the suit, which originally sought $140 million in damages, was settled for less than $30 million. In March 2015, the Cleveland Clinic announced a partnership with Theranos to test its technology and decrease the cost of lab tests. In July 2015, Theranos became the lab-work provider for Pennsylvania insurers AmeriHealth Caritas and Capital Blue Cross. The same month, the Food and Drug Administration approved the use of the company's fingerstick blood testing device for the herpes simplex virus (HSV-1) outside a clinical laboratory setting. Theranos was named the 2015 Bioscience Company of the Year by the Arizona BioIndustry Association (AzBio).
==== Encoded combinatorial libraries ==== When dealing with a non-peptide organic libraries library, it is not as simple to determine the identity of the content of a bead as in the case of a peptide one. In order to circumvent this difficulty, methods have been developed to attach molecules that encode the structure of the compound formed in the bead to the beads, in parallel with the synthesis of the library. Ohlmeyer and his colleagues published a binary encoding method. They used mixtures of 18 tagging molecules that, after cleaving them from the beads, could be identified by Electron Capture Gas Chromatography. Sarkar et al. describe chiral oligomers of pentenoic amides (COPAs) that can be used to construct mass encoded OBOC libraries. Kerr et al. introduced an innovative encoding method. An orthogonally protected removable bifunctional linker was attached to the beads. One end of the linker was used to attach the non-natural building blocks of the library, while encoding amino acid triplets were linked to the other end. The building blocks were non-natural amino acids and the series of their encoding amino acid triplets could be determined by Edman degradation. The important aspect of this kind of encoding was the possibility to cleave down from the beads the library members together with their attached encoding tags forming a soluble library. The same approach was used by Nikolajev et al. for encoding with peptides. In 1992, Brenner and Lerner introduced DNA sequences to encode the beads of the solid support that proved to be the most successful encoding method.
== Effects of consumption == The nature of effects will largely depend on the cultivar of the kava plant and the form of its consumption. Traditionally, only noble kava cultivars have been consumed, as they are accepted as safe and produce desired effects. The specific effects of various noble kavas depend on various factors, such as the cultivar used (and the related specific composition of kavalactones), age of the plant, and method of consumption. However, it can be stated that in general, noble kava produces a state of calmness, relaxation, and well-being without diminishing cognitive performance. Kava may produce an initial talkative period, followed by muscle relaxation and eventual sleepiness. The beverage has initial numbing and astringent effect in the mouth caused by the local anesthetic action of kavalactones and chewing it has local anesthetic effects similar to that of cocaine and longer lasting than benzocaine. As noted in one of the earliest Western publications on kava (1886): "A well prepared Kava potion drunk in small quantities produces only pleasant changes in behavior. It is therefore a slightly stimulating drink which helps relieve great fatigue. It relaxes the body after strenuous efforts, clarifies the mind and sharpens the mental faculties". Despite its psychoactive effects, kava is not considered to be physically addictive and its use does not lead to dependency.
Sources: en.wikipedia.org
The MR vaccine (abbreviated "MRV") is a vaccine for measles and rubella, not mumps. In 2014, the World Health Organization reported it as used in a "few (unidentified) countries". A MRV delivered by a microneedle patch was the subject of a study reported in 2024.
An improved reaction developed by chemist Karl Barry Sharpless involves the copper (I) catalyst, which couples azide with terminal alkyne that only give 1,4 substituted 1,2,3 triazoles in high yields (shown below in Figure 11). The mechanistic study suggests a stepwise reaction. The Cu (I) first couples with acetylenes, and then it reacts with azide to generate a six-membered intermediate. The process is very robust that it occurs at pH ranging from 4 to 12, and copper (II) sulfate is often used as a catalyst in the presence of a reducing agent.
is electron mobility E is the electric field across the depletion region Dn is the diffusion coefficient for electrons Gn is the rate of generation of electrons Rn is the rate of recombination of electrons Similarly, for holes:
Turtles have two or more accessory urinary bladders, located lateral to the neck of the urinary bladder and dorsal to the pubis, occupying a significant portion of their body cavity. Their bladder is also usually bilobed with a left and right section. The right section is located under the liver, which prevents large stones from remaining in that side while the left section is more likely to have calculi.
Sources: en.wikipedia.org
A few dozen American farmers purchased varying amounts of land by a variety of means including finding investors and selling off land holdings. Many followed the ethanol company model and formed an LLC with investments from neighboring farmers, friends, and family while some turned to investment companies. Some soy farmers either liquidated their Brazilian assets or switched to remote management from the US to return to farming there and implement new farming and business practices to make their US farms more productive. Others planned to sell their now expensive Bahia land to buy land cheaper land in the frontier regions of Piauí or Tocantins to create more soybean farms.
== Effect on sleep architecture == In a small study of 14 subjects, ibutamoren dosed at 25 mg/day at bedtime was shown to increase rapid eye movement sleep by 20% and 50% in young and older subjects respectively. Treatment with ibutamoren also resulted in an approximate 50% increase in slow-wave sleep in young subjects.
The 164th Brigade commanded the 327th Infantry Regiment and the 328th Infantry Regiment and the 321st Machine Gun Battalion. Also in the division were the 157th Field Artillery Brigade, composed of the 319th, 320th and 321st Field Artillery Regiments and the 307th Trench Mortar Battery; a divisional troops contingent, and a division train. The division sailed to Europe in May 1918 to join the American Expeditionary Forces (AEF), commanded by General John Pershing, on the Western Front. The 82nd Airborne Division was the first of five airborne divisions (11th, 13th, 17th, 82nd and 101st) to be formed in the United States during World War II. It was officially activated on 15 August 1942 at Fort Bragg in North Carolina, under the command of Major General Bradley with the classification of an airborne division.
==== Development ==== The length of time before hatching is highly variable; smaller eggs in warmer waters are the fastest to hatch, and newborns can emerge after as little as a few days. Larger eggs in colder waters can develop for over a year before hatching. The process from spawning to hatching follows a similar trajectory in all species, the main variable being the amount of yolk available to the young and when it is absorbed by the embryo. Unlike most other molluscs, cephalopods do not have a morphologically distinct larval stage. Instead, the juveniles of coleoids are known as paralarvae. Paralarvae have been observed only in members of the Octopoda and Teuthida (which constitutes the modern definition of Coleoidea). In contrast, hatchling nautili are not referred to by a specific technical term, as they resemble miniatures of the adults. Neonate cephalopods quickly learn how to hunt, using encounters with prey to refine their strategies. Growth in juveniles is usually allometric, whilst adult growth is isometric.
Byzantine territories fragmented into competing political entities. The crusaders crowned Baldwin I as the ruler of a new Latin Empire in Constantinople; it soon suffered a crushing defeat against the Bulgarians in 1205. It also failed to expand west or east, where three successor states had formed: the Empire of Nicaea and the Empire of Trebizond in Asia Minor, and the Despotate of Epirus on the Adriatic. The Venetians acquired many ports and islands, and the Principality of Achaea emerged in southern Greece. Trebizond lost the key port of Sinope in 1214 and thereafter played little role away from the southeastern Black Sea. For a time, Epirus appeared well placed to reclaim Constantinople from the Latins, and its ruler Theodore Doukas crowned himself emperor, but he suffered a critical defeat at the Battle of Klokotnitsa in 1230, and Epirote power waned. Nicaea, ruled by the Laskarid dynasty and drawing on both Byzantine refugees and local populations, blocked the Latins and the Seljuks of Rum from expanding east and west respectively. John III (r. 1221–1254) strengthened Nicaea militarily, economically, and diplomatically. He discouraged imports and promoted local production, and he made many diplomatic treaties, especially after Mongol armies ravaged Bulgaria and defeated Rum between 1237 and 1243. This chaos was an opportunity for John, and he fought many successful campaigns against the states disrupted by the Mongol invasions. Soon after his death, his grandson was usurped by Michael VIII, founder of the Palaiologos dynasty, who recaptured Constantinople in 1261.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.